Osama Hamdy, M.B.,B.Ch., M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Type 2 | 47 | 2023 | 12148 | 3.380 |
Why?
|
| Nutrition Therapy | 9 | 2021 | 102 | 3.330 |
Why?
|
| Food, Formulated | 4 | 2020 | 101 | 2.320 |
Why?
|
| Weight Loss | 20 | 2024 | 2684 | 2.100 |
Why?
|
| Obesity | 28 | 2024 | 12947 | 1.830 |
Why?
|
| Life Style | 16 | 2023 | 3917 | 1.370 |
Why?
|
| Hyperglycemia | 4 | 2023 | 1376 | 1.320 |
Why?
|
| Dairy Products | 3 | 2021 | 490 | 1.260 |
Why?
|
| Diabetes Mellitus | 11 | 2020 | 5840 | 1.210 |
Why?
|
| Diet, Carbohydrate-Restricted | 2 | 2021 | 262 | 1.140 |
Why?
|
| Blood Glucose | 18 | 2024 | 6391 | 1.140 |
Why?
|
| Diet, Fat-Restricted | 2 | 2020 | 329 | 1.110 |
Why?
|
| Blood Glucose Self-Monitoring | 5 | 2022 | 467 | 1.090 |
Why?
|
| Prediabetic State | 4 | 2018 | 545 | 1.050 |
Why?
|
| Islam | 5 | 2022 | 70 | 1.040 |
Why?
|
| Nutrition Policy | 2 | 2021 | 471 | 1.040 |
Why?
|
| Overweight | 6 | 2020 | 2417 | 0.990 |
Why?
|
| Body Weight | 7 | 2021 | 4618 | 0.910 |
Why?
|
| Fasting | 5 | 2022 | 1603 | 0.790 |
Why?
|
| Diabetes Mellitus, Type 1 | 6 | 2024 | 3415 | 0.790 |
Why?
|
| Hypoglycemic Agents | 10 | 2024 | 3085 | 0.760 |
Why?
|
| Nutritional Status | 9 | 2020 | 1615 | 0.760 |
Why?
|
| Nutrition Assessment | 3 | 2021 | 728 | 0.760 |
Why?
|
| Insulin Infusion Systems | 2 | 2024 | 217 | 0.750 |
Why?
|
| Satiation | 1 | 2019 | 83 | 0.660 |
Why?
|
| Fatty Acids, Nonesterified | 1 | 2021 | 393 | 0.660 |
Why?
|
| Postprandial Period | 2 | 2024 | 315 | 0.630 |
Why?
|
| Nutritional Physiological Phenomena | 1 | 2020 | 363 | 0.610 |
Why?
|
| Hunger | 1 | 2019 | 206 | 0.590 |
Why?
|
| Eating | 2 | 2021 | 1539 | 0.550 |
Why?
|
| Religion | 1 | 2020 | 372 | 0.540 |
Why?
|
| Hyperlipidemias | 3 | 2020 | 771 | 0.540 |
Why?
|
| Metformin | 2 | 2023 | 906 | 0.540 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2020 | 339 | 0.520 |
Why?
|
| Remote Consultation | 1 | 2018 | 237 | 0.520 |
Why?
|
| Biosensing Techniques | 1 | 2021 | 650 | 0.500 |
Why?
|
| Standard of Care | 2 | 2020 | 551 | 0.490 |
Why?
|
| Cultural Characteristics | 2 | 2015 | 251 | 0.490 |
Why?
|
| Thyroidectomy | 1 | 2020 | 907 | 0.460 |
Why?
|
| Hyperinsulinism | 1 | 2016 | 400 | 0.430 |
Why?
|
| Diet, Reducing | 5 | 2018 | 485 | 0.430 |
Why?
|
| Exercise | 12 | 2024 | 5890 | 0.390 |
Why?
|
| Adipose Tissue | 5 | 2007 | 3312 | 0.380 |
Why?
|
| Egypt | 3 | 2021 | 97 | 0.350 |
Why?
|
| Insulin Resistance | 7 | 2021 | 3963 | 0.350 |
Why?
|
| Thyroid Neoplasms | 2 | 2021 | 2332 | 0.350 |
Why?
|
| Humans | 77 | 2024 | 761504 | 0.340 |
Why?
|
| Risk Reduction Behavior | 4 | 2015 | 1112 | 0.340 |
Why?
|
| Cardiovascular Diseases | 7 | 2021 | 15500 | 0.340 |
Why?
|
| Pulmonary Edema | 3 | 2001 | 409 | 0.330 |
Why?
|
| Hypoglycemia | 1 | 2016 | 883 | 0.330 |
Why?
|
| Patient Compliance | 1 | 2019 | 2690 | 0.320 |
Why?
|
| Nutritional Support | 1 | 2010 | 173 | 0.310 |
Why?
|
| Hospital Costs | 1 | 2014 | 947 | 0.310 |
Why?
|
| Intra-Abdominal Fat | 1 | 2013 | 613 | 0.300 |
Why?
|
| Endothelium, Vascular | 7 | 2007 | 4431 | 0.300 |
Why?
|
| Hepatitis C, Chronic | 1 | 2015 | 1032 | 0.290 |
Why?
|
| Feeding Behavior | 7 | 2020 | 3188 | 0.280 |
Why?
|
| Dietary Proteins | 2 | 2014 | 952 | 0.280 |
Why?
|
| Skin | 4 | 2006 | 4484 | 0.280 |
Why?
|
| Endocrine Glands | 1 | 2005 | 102 | 0.250 |
Why?
|
| Neuropeptide Y | 3 | 2001 | 192 | 0.250 |
Why?
|
| Middle Aged | 31 | 2024 | 220895 | 0.240 |
Why?
|
| Weight Gain | 2 | 2017 | 2348 | 0.230 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2018 | 4016 | 0.220 |
Why?
|
| Incretins | 1 | 2024 | 99 | 0.220 |
Why?
|
| Insulin | 6 | 2024 | 6596 | 0.210 |
Why?
|
| Algorithms | 5 | 2016 | 14031 | 0.210 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3084 | 0.200 |
Why?
|
| Microcirculation | 3 | 2003 | 1273 | 0.200 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 3204 | 0.200 |
Why?
|
| Male | 31 | 2024 | 360804 | 0.200 |
Why?
|
| Waist Circumference | 2 | 2018 | 935 | 0.200 |
Why?
|
| Diabetic Neuropathies | 2 | 2007 | 405 | 0.200 |
Why?
|
| Cross-Over Studies | 2 | 2019 | 2078 | 0.190 |
Why?
|
| Female | 33 | 2024 | 392644 | 0.190 |
Why?
|
| Goiter, Nodular | 1 | 2021 | 28 | 0.190 |
Why?
|
| Adult | 26 | 2024 | 221177 | 0.190 |
Why?
|
| Counseling | 3 | 2021 | 1547 | 0.190 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2020 | 9280 | 0.190 |
Why?
|
| Dietary Supplements | 1 | 2014 | 3415 | 0.190 |
Why?
|
| Glycemic Index | 2 | 2016 | 396 | 0.190 |
Why?
|
| Blood Pressure | 7 | 2020 | 8481 | 0.190 |
Why?
|
| Energy Intake | 3 | 2020 | 2134 | 0.190 |
Why?
|
| Risk Factors | 12 | 2023 | 74206 | 0.190 |
Why?
|
| Endoscopy, Gastrointestinal | 2 | 2017 | 874 | 0.180 |
Why?
|
| Diet | 6 | 2021 | 8075 | 0.180 |
Why?
|
| Glucagon-Like Peptide 1 | 2 | 2016 | 364 | 0.180 |
Why?
|
| Length of Stay | 1 | 2014 | 6425 | 0.180 |
Why?
|
| Abdomen | 1 | 2006 | 1128 | 0.180 |
Why?
|
| Glucose | 2 | 2022 | 4346 | 0.170 |
Why?
|
| Pandemics | 1 | 2020 | 8654 | 0.170 |
Why?
|
| Thiazolidinediones | 3 | 2009 | 461 | 0.170 |
Why?
|
| Peptide YY | 2 | 2019 | 136 | 0.170 |
Why?
|
| Islet Amyloid Polypeptide | 1 | 2019 | 42 | 0.170 |
Why?
|
| Exudates and Transudates | 1 | 2000 | 174 | 0.170 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 2 | 2003 | 1651 | 0.160 |
Why?
|
| Cholecystokinin | 1 | 2019 | 117 | 0.160 |
Why?
|
| Leptin | 3 | 2019 | 1597 | 0.160 |
Why?
|
| Reflex | 1 | 2001 | 376 | 0.160 |
Why?
|
| Clinical Trials as Topic | 3 | 2011 | 8002 | 0.160 |
Why?
|
| Body Mass Index | 7 | 2020 | 12953 | 0.160 |
Why?
|
| Bariatric Surgery | 3 | 2017 | 992 | 0.160 |
Why?
|
| Pilot Projects | 3 | 2022 | 8631 | 0.160 |
Why?
|
| Aged | 16 | 2022 | 169289 | 0.160 |
Why?
|
| Dietary Fiber | 1 | 2022 | 759 | 0.160 |
Why?
|
| Body Composition | 3 | 2018 | 2426 | 0.150 |
Why?
|
| Ghrelin | 1 | 2019 | 252 | 0.150 |
Why?
|
| Liver | 1 | 2013 | 7529 | 0.140 |
Why?
|
| Glucagon | 1 | 2019 | 532 | 0.140 |
Why?
|
| Adipokines | 1 | 2019 | 310 | 0.140 |
Why?
|
| Cholesterol, HDL | 2 | 2020 | 1814 | 0.140 |
Why?
|
| Vasodilation | 1 | 2001 | 962 | 0.140 |
Why?
|
| Thyroid Nodule | 2 | 2021 | 764 | 0.130 |
Why?
|
| Seeds | 1 | 2016 | 122 | 0.130 |
Why?
|
| Behavior Therapy | 2 | 2018 | 879 | 0.130 |
Why?
|
| Health Literacy | 1 | 2020 | 444 | 0.120 |
Why?
|
| Dietary Fats, Unsaturated | 1 | 2016 | 224 | 0.120 |
Why?
|
| Vascular Diseases | 1 | 2003 | 1161 | 0.120 |
Why?
|
| Dietary Fats | 2 | 2020 | 1995 | 0.120 |
Why?
|
| Cytokines | 3 | 2005 | 7396 | 0.120 |
Why?
|
| Boston | 2 | 2019 | 9326 | 0.120 |
Why?
|
| Dietary Carbohydrates | 2 | 2016 | 891 | 0.120 |
Why?
|
| Anastomosis, Roux-en-Y | 1 | 2014 | 86 | 0.120 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2017 | 385 | 0.110 |
Why?
|
| Follow-Up Studies | 5 | 2020 | 39106 | 0.110 |
Why?
|
| Lymph Node Excision | 1 | 2020 | 1271 | 0.110 |
Why?
|
| Cholesterol | 1 | 2022 | 2904 | 0.110 |
Why?
|
| Gastroplasty | 1 | 2015 | 157 | 0.110 |
Why?
|
| Group Processes | 1 | 2014 | 228 | 0.110 |
Why?
|
| Retrospective Studies | 6 | 2021 | 80636 | 0.100 |
Why?
|
| Axons | 1 | 2001 | 1674 | 0.100 |
Why?
|
| Taiwan | 1 | 2014 | 521 | 0.100 |
Why?
|
| United States | 7 | 2021 | 72334 | 0.100 |
Why?
|
| Exercise Therapy | 1 | 2019 | 929 | 0.100 |
Why?
|
| Nitric Oxide | 1 | 2001 | 2135 | 0.100 |
Why?
|
| Culture | 1 | 2016 | 623 | 0.100 |
Why?
|
| Lymphatic Metastasis | 1 | 2020 | 2915 | 0.100 |
Why?
|
| Adiponectin | 4 | 2007 | 1113 | 0.100 |
Why?
|
| Iontophoresis | 2 | 2002 | 74 | 0.100 |
Why?
|
| Adiposity | 2 | 2019 | 1878 | 0.100 |
Why?
|
| Quality of Life | 4 | 2023 | 13367 | 0.100 |
Why?
|
| Mexico | 1 | 2014 | 764 | 0.090 |
Why?
|
| Prognosis | 3 | 2021 | 29625 | 0.090 |
Why?
|
| Practice Guidelines as Topic | 3 | 2017 | 7390 | 0.090 |
Why?
|
| Endocrinology | 1 | 2016 | 442 | 0.090 |
Why?
|
| Disease-Free Survival | 1 | 2020 | 6814 | 0.080 |
Why?
|
| Dipeptidyl Peptidase 4 | 1 | 2009 | 91 | 0.080 |
Why?
|
| Muscle, Skeletal | 1 | 2024 | 4948 | 0.080 |
Why?
|
| Remission Induction | 1 | 2015 | 2396 | 0.080 |
Why?
|
| Venoms | 1 | 2009 | 94 | 0.080 |
Why?
|
| Disease Management | 1 | 2020 | 2508 | 0.080 |
Why?
|
| Drug Monitoring | 1 | 2015 | 962 | 0.080 |
Why?
|
| Urban Population | 2 | 2014 | 2036 | 0.080 |
Why?
|
| Patient Education as Topic | 2 | 2017 | 2319 | 0.080 |
Why?
|
| Nutritional Requirements | 1 | 2010 | 276 | 0.080 |
Why?
|
| Prevalence | 4 | 2021 | 15732 | 0.080 |
Why?
|
| Enteral Nutrition | 1 | 2014 | 794 | 0.080 |
Why?
|
| Health Resources | 1 | 2014 | 935 | 0.080 |
Why?
|
| Sulfonylurea Compounds | 1 | 2009 | 219 | 0.070 |
Why?
|
| Abdominal Fat | 1 | 2009 | 221 | 0.070 |
Why?
|
| Young Adult | 5 | 2021 | 59243 | 0.070 |
Why?
|
| Longitudinal Studies | 2 | 2023 | 14605 | 0.070 |
Why?
|
| Critical Care | 1 | 2020 | 2696 | 0.070 |
Why?
|
| Glucose Tolerance Test | 3 | 2007 | 1178 | 0.070 |
Why?
|
| PPAR alpha | 1 | 2008 | 175 | 0.070 |
Why?
|
| Micronutrients | 1 | 2010 | 382 | 0.070 |
Why?
|
| Treatment Outcome | 6 | 2020 | 64680 | 0.070 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 2 | 2007 | 277 | 0.070 |
Why?
|
| Rural Population | 2 | 2014 | 2285 | 0.070 |
Why?
|
| Sex Factors | 1 | 2020 | 10552 | 0.070 |
Why?
|
| Inflammation | 2 | 2020 | 10773 | 0.060 |
Why?
|
| Lipids | 3 | 2014 | 3341 | 0.060 |
Why?
|
| Survival Rate | 1 | 2020 | 12725 | 0.060 |
Why?
|
| Program Development | 1 | 2012 | 1297 | 0.060 |
Why?
|
| Guidelines as Topic | 1 | 2012 | 1386 | 0.060 |
Why?
|
| PPAR gamma | 1 | 2008 | 484 | 0.060 |
Why?
|
| Waist-Hip Ratio | 1 | 2006 | 518 | 0.060 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 1 | 2009 | 311 | 0.060 |
Why?
|
| Drug Therapy, Combination | 1 | 2015 | 6310 | 0.060 |
Why?
|
| Inpatients | 1 | 2016 | 2548 | 0.060 |
Why?
|
| Nitroprusside | 2 | 2002 | 272 | 0.060 |
Why?
|
| Obesity, Morbid | 1 | 2015 | 1277 | 0.060 |
Why?
|
| Benzamides | 1 | 2009 | 1370 | 0.060 |
Why?
|
| Combined Modality Therapy | 1 | 2015 | 8529 | 0.050 |
Why?
|
| Chromans | 1 | 2003 | 117 | 0.050 |
Why?
|
| Acupuncture Therapy | 1 | 2007 | 486 | 0.050 |
Why?
|
| Nitroglycerin | 1 | 2003 | 329 | 0.050 |
Why?
|
| Acetylcholine | 2 | 2002 | 629 | 0.050 |
Why?
|
| Keratan Sulfate | 1 | 2001 | 17 | 0.050 |
Why?
|
| Brachial Artery | 1 | 2003 | 366 | 0.050 |
Why?
|
| Incidence | 1 | 2020 | 21353 | 0.050 |
Why?
|
| Tumor Necrosis Factor-alpha | 4 | 2008 | 4352 | 0.050 |
Why?
|
| Sodium Chloride | 2 | 2002 | 587 | 0.050 |
Why?
|
| Evaluation Studies as Topic | 1 | 2003 | 1624 | 0.050 |
Why?
|
| Administration, Inhalation | 1 | 2024 | 1157 | 0.050 |
Why?
|
| Chondroitin Sulfate Proteoglycans | 1 | 2001 | 141 | 0.050 |
Why?
|
| Hospitals | 1 | 2014 | 3882 | 0.050 |
Why?
|
| NG-Nitroarginine Methyl Ester | 1 | 2001 | 260 | 0.050 |
Why?
|
| Cognition | 1 | 2018 | 6990 | 0.050 |
Why?
|
| Ganglionic Blockers | 1 | 2000 | 4 | 0.050 |
Why?
|
| Hexamethonium | 1 | 2000 | 17 | 0.040 |
Why?
|
| Kidney Diseases | 1 | 2011 | 2091 | 0.040 |
Why?
|
| Monosaccharide Transport Proteins | 1 | 2001 | 436 | 0.040 |
Why?
|
| Body Water | 1 | 2001 | 340 | 0.040 |
Why?
|
| Sclera | 1 | 2001 | 190 | 0.040 |
Why?
|
| Hydrostatic Pressure | 1 | 2000 | 98 | 0.040 |
Why?
|
| Evidence-Based Medicine | 1 | 2012 | 3688 | 0.040 |
Why?
|
| Nicotinic Antagonists | 1 | 2000 | 94 | 0.040 |
Why?
|
| Medulla Oblongata | 1 | 2001 | 248 | 0.040 |
Why?
|
| Diet Therapy | 1 | 2020 | 151 | 0.040 |
Why?
|
| Blood Flow Velocity | 1 | 2003 | 1371 | 0.040 |
Why?
|
| Diabetic Angiopathies | 2 | 2003 | 803 | 0.040 |
Why?
|
| Receptors, Neuropeptide | 1 | 1999 | 106 | 0.040 |
Why?
|
| Prospective Studies | 2 | 2020 | 54425 | 0.040 |
Why?
|
| Sleep | 1 | 2014 | 4768 | 0.040 |
Why?
|
| Vagus Nerve | 1 | 2001 | 458 | 0.040 |
Why?
|
| Forearm | 1 | 2001 | 427 | 0.040 |
Why?
|
| Systole | 1 | 2020 | 936 | 0.040 |
Why?
|
| Double-Blind Method | 2 | 2009 | 12341 | 0.040 |
Why?
|
| Proteins | 3 | 2003 | 6032 | 0.040 |
Why?
|
| Age Factors | 1 | 2014 | 18395 | 0.040 |
Why?
|
| Macrophages, Alveolar | 1 | 2000 | 412 | 0.040 |
Why?
|
| Thrombin | 1 | 2000 | 591 | 0.040 |
Why?
|
| Sex Hormone-Binding Globulin | 1 | 2000 | 550 | 0.040 |
Why?
|
| Arginine | 1 | 2001 | 934 | 0.040 |
Why?
|
| Rats, Wistar | 1 | 2001 | 1848 | 0.040 |
Why?
|
| Peptides | 1 | 2009 | 4358 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2009 | 10209 | 0.030 |
Why?
|
| Foot | 1 | 2001 | 575 | 0.030 |
Why?
|
| Time Factors | 4 | 2014 | 39967 | 0.030 |
Why?
|
| Interleukin-6 | 2 | 2003 | 3208 | 0.030 |
Why?
|
| Hospitalization | 1 | 2016 | 10723 | 0.030 |
Why?
|
| Fibrinogen | 1 | 2000 | 888 | 0.030 |
Why?
|
| Self Efficacy | 1 | 2020 | 638 | 0.030 |
Why?
|
| Health Promotion | 1 | 2008 | 2214 | 0.030 |
Why?
|
| Costa Rica | 1 | 2016 | 180 | 0.030 |
Why?
|
| Protein Biosynthesis | 1 | 2003 | 2113 | 0.030 |
Why?
|
| Capillary Permeability | 1 | 1999 | 773 | 0.030 |
Why?
|
| Rats | 3 | 2001 | 23742 | 0.030 |
Why?
|
| Thiazoles | 1 | 2003 | 1517 | 0.030 |
Why?
|
| Pregnancy in Diabetics | 1 | 2017 | 197 | 0.030 |
Why?
|
| Expert Systems | 1 | 1995 | 79 | 0.030 |
Why?
|
| Latin America | 1 | 2016 | 410 | 0.030 |
Why?
|
| Venezuela | 1 | 2014 | 73 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2001 | 3810 | 0.030 |
Why?
|
| Cornea | 1 | 2001 | 1333 | 0.030 |
Why?
|
| Ultrasonography | 1 | 2006 | 5972 | 0.030 |
Why?
|
| Collagen | 1 | 2001 | 2638 | 0.030 |
Why?
|
| Educational Status | 1 | 2020 | 2522 | 0.030 |
Why?
|
| Minerals | 1 | 2014 | 283 | 0.030 |
Why?
|
| Cross-Cultural Comparison | 1 | 2016 | 635 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2001 | 6228 | 0.030 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2002 | 2273 | 0.020 |
Why?
|
| Brazil | 1 | 2015 | 1230 | 0.020 |
Why?
|
| Liver Cirrhosis | 1 | 2021 | 1935 | 0.020 |
Why?
|
| Coronary Disease | 1 | 2005 | 5914 | 0.020 |
Why?
|
| Respiratory Insufficiency | 1 | 1999 | 1230 | 0.020 |
Why?
|
| Aged, 80 and over | 2 | 2014 | 58976 | 0.020 |
Why?
|
| Antihypertensive Agents | 1 | 2000 | 2024 | 0.020 |
Why?
|
| Comorbidity | 2 | 2015 | 10508 | 0.020 |
Why?
|
| Aspirin | 1 | 2002 | 3133 | 0.020 |
Why?
|
| Food | 1 | 2014 | 774 | 0.020 |
Why?
|
| Cohort Studies | 3 | 2021 | 41487 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2007 | 15842 | 0.020 |
Why?
|
| Testosterone | 1 | 2000 | 2472 | 0.020 |
Why?
|
| Beverages | 1 | 2014 | 821 | 0.020 |
Why?
|
| Endothelins | 1 | 2008 | 127 | 0.020 |
Why?
|
| Health Personnel | 1 | 2022 | 3335 | 0.020 |
Why?
|
| Pregnancy | 2 | 2022 | 29874 | 0.020 |
Why?
|
| Publishing | 1 | 1995 | 833 | 0.020 |
Why?
|
| Acupuncture Analgesia | 1 | 2007 | 63 | 0.020 |
Why?
|
| Equipment Design | 1 | 2015 | 3510 | 0.020 |
Why?
|
| Reference Values | 1 | 2014 | 4920 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2000 | 11076 | 0.020 |
Why?
|
| Consensus | 1 | 2016 | 3123 | 0.020 |
Why?
|
| Hypertension | 2 | 2003 | 8540 | 0.020 |
Why?
|
| Sensory Thresholds | 1 | 2007 | 377 | 0.020 |
Why?
|
| Vitamins | 1 | 2014 | 1635 | 0.020 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2008 | 691 | 0.020 |
Why?
|
| Risk | 1 | 2017 | 9610 | 0.010 |
Why?
|
| Medicaid | 1 | 2017 | 2818 | 0.010 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2007 | 1126 | 0.010 |
Why?
|
| Motor Activity | 1 | 2014 | 2715 | 0.010 |
Why?
|
| C-Reactive Protein | 2 | 2007 | 3826 | 0.010 |
Why?
|
| Hormones, Ectopic | 1 | 2003 | 37 | 0.010 |
Why?
|
| Leukocyte Count | 1 | 2007 | 1596 | 0.010 |
Why?
|
| Socioeconomic Factors | 1 | 2017 | 7827 | 0.010 |
Why?
|
| Vasculitis | 1 | 2007 | 521 | 0.010 |
Why?
|
| Risk Assessment | 2 | 2015 | 23995 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 2014 | 5247 | 0.010 |
Why?
|
| Resistin | 1 | 2003 | 172 | 0.010 |
Why?
|
| Animals | 4 | 2008 | 168459 | 0.010 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2007 | 1164 | 0.010 |
Why?
|
| Absorptiometry, Photon | 1 | 2007 | 1738 | 0.010 |
Why?
|
| Laser-Doppler Flowmetry | 1 | 2002 | 239 | 0.010 |
Why?
|
| Alcohol Drinking | 1 | 2014 | 4028 | 0.010 |
Why?
|
| Microscopy, Atomic Force | 1 | 2001 | 253 | 0.010 |
Why?
|
| Indicators and Reagents | 1 | 2001 | 462 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2021 | 26125 | 0.010 |
Why?
|
| Reserpine | 1 | 1999 | 63 | 0.010 |
Why?
|
| Triglycerides | 1 | 2007 | 2461 | 0.010 |
Why?
|
| Adrenergic alpha-Antagonists | 1 | 1999 | 174 | 0.010 |
Why?
|
| Medicare | 1 | 2017 | 6770 | 0.010 |
Why?
|
| Placebos | 1 | 2003 | 1667 | 0.010 |
Why?
|
| Adrenergic Uptake Inhibitors | 1 | 1999 | 186 | 0.010 |
Why?
|
| Microscopy, Electron | 1 | 2001 | 2561 | 0.010 |
Why?
|
| Organometallic Compounds | 1 | 2001 | 647 | 0.010 |
Why?
|
| Vasodilator Agents | 1 | 2002 | 973 | 0.010 |
Why?
|
| Staining and Labeling | 1 | 2001 | 1085 | 0.010 |
Why?
|
| Norepinephrine | 1 | 1999 | 897 | 0.010 |
Why?
|
| Pain Measurement | 1 | 2007 | 3550 | 0.010 |
Why?
|
| Fibrin | 1 | 1999 | 507 | 0.010 |
Why?
|
| Pulmonary Circulation | 1 | 1999 | 737 | 0.010 |
Why?
|
| Adolescent | 3 | 2017 | 88319 | 0.010 |
Why?
|
| Water | 1 | 2002 | 1411 | 0.010 |
Why?
|
| Decision Making, Computer-Assisted | 1 | 1995 | 146 | 0.010 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 1999 | 1241 | 0.010 |
Why?
|
| Information Services | 1 | 1995 | 236 | 0.010 |
Why?
|
| Indoles | 1 | 2001 | 1833 | 0.010 |
Why?
|
| Pain | 1 | 2007 | 5073 | 0.010 |
Why?
|
| Health Behavior | 1 | 2000 | 2643 | 0.000 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 1999 | 10766 | 0.000 |
Why?
|
| Heart Diseases | 1 | 2000 | 2781 | 0.000 |
Why?
|
| Massachusetts | 1 | 2000 | 8830 | 0.000 |
Why?
|
| Diabetic Retinopathy | 1 | 1995 | 1274 | 0.000 |
Why?
|
| Child | 2 | 2007 | 80153 | 0.000 |
Why?
|
| Predictive Value of Tests | 1 | 2000 | 15266 | 0.000 |
Why?
|
| Mice | 1 | 2008 | 81525 | 0.000 |
Why?
|
| Aging | 1 | 2000 | 8708 | 0.000 |
Why?
|
| Quality of Health Care | 1 | 1995 | 4330 | 0.000 |
Why?
|
| Mass Screening | 1 | 1995 | 5428 | 0.000 |
Why?
|